SIGLEC1 and posterior cortical atrophy: Strömvall et al. found that PCa patients with low CD169 immunostaining in metastasis-free regional lymph nodes had worse outcomes (significantly shorter survival time) than patients with high CD169 scores—200 (95% CI 178–221) vs. 232 (95% CI 226–239) months [4].